Point State Capital LP Prothena Corp Public LTD CO Transaction History

Point State Capital LP

  • $3.92 Billion
  • Q2 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2018

May 15, 2018
SELL
$27.95 - $45.04 $6.87 Million - $11.1 Million
-245,890 Closed
0 $0
Q4 2017

Feb 14, 2018
SELL
$35.44 - $63.76 $3.77 Million - $6.79 Million
-106,510 Reduced 30.22%
245,890 $9.22 Million
Q3 2017

Nov 14, 2017
BUY
$53.83 - $67.75 $4.3 Million - $5.41 Million
79,900 Added 29.32%
352,400 $22.8 Million
Q2 2017

Aug 14, 2017
BUY
N/A
272,500
272,500 $14.7 Million

Others Institutions Holding PRTA

# of Institutions
182
Shares Held
42.7M
Call Options Held
77.7K
Put Options Held
92.7K
View Full List

About PROTHENA CORP PUBLIC LTD CO

PRTA Quotes by TradingView
  • Ticker PRTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,922,800
  • Market Cap $783M
  • Description
  • Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...
More about PRTA
Track This Portfolio

Track Point State Capital LP Portfolio

Follow Point State Capital LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Point State Capital LP, based on Form 13F filings with the SEC.

News

Stay updated on Point State Capital LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email